N1VO34 Stock Price and Chart — BMFBOVESPA:N1VO34

Key facts today

The US FDA warned of dosing errors with Novo Nordisk's weight loss drug semaglutide, causing adverse events and hospitalizations due to measurement confusion.

Novo Nordisk is recognized as a leading company in the European markets, particularly noted for its diabetes and weight loss treatments, marking its prominence in the pharmaceutical industry.

Novo Nordisk's Ozempic and Wegovy challenge DexCom, risking market share loss to rivals like Abbott, showing Novo's market impact.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.